Last Updated : April 30, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Azilect | Rasagiline mesylate | Parkinson's disease | N/A | Complete | ||
| Azilect | Rasagiline mesylate | Parkinson's disease | Do not list | Complete | ||
| Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | ||
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete | ||
| Avastin (with capecitabine) | Bevacizumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Platinum Resistant Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Avastin | Bevacizumab | Withdrawn |
Last Updated : April 30, 2024